The analyst writes that 4DMT's platform has generated competitive gene therapies and been clinically validated through its five ongoing clinical programs.
BMO notes that 4D Molecular Therapeutics' Wet Age-Related Macular Degeneration (wet AMD) program addresses key limitations of approved/investigational therapies and can potentially confer a $5 billion opportunity.
The company's cystic Fibrosis asset 4D-710 can be the first therapy delivering clinical effects in patients without treatment options, potentially unlocking around $3 billion opportunity.
In cystic fibrosis, a 3-5%+ improvement in FEV1 can drive FDMT stock over 50% higher and render the stock an attractive acquisition target.
Potential announcements around partnerships would trigger further upside.
Price Action: FDMT shares are up 0.96% at $21.47 on the last check Monday.
